Protocol Ledger

NCT04620733 · Phase III · COMPLETED

RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Interventional Phase III clinical trial protocol NCT04620733 sponsored by Gilead Sciences in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-04-21 Enrollment: 193 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04620733
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)193 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04620733
Protocol FieldVerified Registry Value
NCT IdentifierNCT04620733
Consolidated Lead SponsorGilead Sciences
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment193 participants (ACTUAL)
Registered Start Date2021-04-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04620733
Hospital Research SiteLocationSite Profile
Stanford Health Care and Stanford Cancer InstituteStanford, CAOpen Hospital Dossier ->
UC Davis Comprehensive Cancer CenterSacramento, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI